Assessment of localisation of vasodilatory response in CTEPH by SPECT imaging

Assessment of localisation of vasodilatory response in CTEPH by SPECT imaging - Vasodilator response localisation in CTEPH with SPECT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33993

Enrollment

Registered

2009-02-11

Start date

2009-02-16

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic thromboembolic pulmonary hypertension increased blood pressure in pulmonary vesels due to chronic pulmonary embolism

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -mean pulmonary artery pressure > 25 mmHg during right heart catherisation/ pulmonary angiography -specific signs of chronic thromboembolism during pulmonary angiography -Ntric monooxide testing during pulmonary angiography cq right heart pressure measuring

Exclusion criteria

Exclusion criteria: -Presence of systemic inflammation. - Patients with pulmonary hypertension associated with collagen vascular disease, congenital heart disease, pulmonary venous hypertension, left heart failure, hypoxemic lung disease (COPD).

Design outcomes

Primary

Measure	Time frame
Macro aggregated albumin (MAA) injected in the peripheral vein distributes via the right heart (right ventricle) and pulmonary artery over both lungs; its distribution reflects the distribution of capillary perfusion at the time of injection. The primary endpoint is the regional (lobar) change of biodistribution of MAA over both lungs under the influence of NO assessed with SPECT. Changes in perfusion counts between obstructed and non-obstructed regions of the lungs will be assessed to determine the vasodilatory response to NO with newly developed software (based upon published algorithms). According to our hypothesis the perfusion in the nonobstructed parts will increase after inhalation of NO. In short, to determine the effect of NO on the regional pulmonary perfusion, using quantitative analysis of the SPECT data.	—

Measure

Time frame

Macro aggregated albumin (MAA) injected in the peripheral vein distributes via the right heart (right ventricle) and pulmonary artery over both lungs; its distribution reflects the distribution of capillary perfusion at the time of injection. The primary endpoint is the regional (lobar) change of biodistribution of MAA over both lungs under the influence of NO assessed with SPECT. Changes in perfusion counts between obstructed and non-obstructed regions of the lungs will be assessed to determine the vasodilatory response to NO with newly developed software (based upon published algorithms). According to our hypothesis the perfusion in the nonobstructed parts will increase after inhalation of NO. In short, to determine the effect of NO on the regional pulmonary perfusion, using quantitative analysis of the SPECT data.

—

Secondary

Measure	Time frame
To define the reproducibility of 99mTc- MAA biodistribution as assessed with SPECT another SPECT perfusion at baseline will be performed.	—

Countries

Netherlands

Outcome results